The Next Big Biotech? NNVC Targets Massive Global Markets

Investors are watching this Stock! ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­

Unsubscribe A message from Interactive Offers    Hidden Biotech Gem Alert: NanoViricides, Inc. (NYSE: NNVC) Poised to Revolutionize Antiviral Therapy Amid COVID-19 Resurgence and Rising Viral Threats! NNVC Emerges with Next-Gen Antiviral Platform! NanoViricides, Inc. (NYSE: NNVC), a clinical-stage company developing broad-spectrum antivirals that target viruses in a way conventional drugs CANNOT! Why is NNVC Unique? Unlike vaccines and antibodies, NanoViricides' approach uses host-mimetic nanomedicine—chemical nanomachines that mimic human cell receptors, binding and neutralizing viruses even as they mutate. Lead Candidate NV-387 The company's lead candidate, NV-387, shows strong antiviral and anti-inflammatory effects, potentially reducing viral complications and cancer recurrence risk. RSV: Completely cured RSV-infected animals. Influenza: Over 200% survival improvement vs. Tamiflu and others. Mpox: Outperformed Tecovirimat in studies; Phase II underway. Other viruses: Effective against herpes, HIV, and more. NV-387's mechanism—binding and neutralizing viruses before cell entry—is predictive of human effectiveness. Why Investors Should Pay Attention: With rising COVID-19 and seasonal viral threats, NanoViricides, Inc. (NYSE: NNVC) is pioneering a therapy viruses cannot easily escape. Broad-spectrum platform resistant to viral escape. Phase II validation with NV-387. Dual action: antiviral + anti-inflammatory. Proven superiority in multiple animal studies. Fast-track approvals via orphan drug pathways. Discover how NNVC is redefining antiviral therapy with host-mimetic nanomedicine. This message is a PAID ADVERTISEMENT for NanoViricides, Inc (NYSE: NNVC) from Interactive Offers. Daily Options Signals, Inc and StockEarnings, Inc has received a fixed fee of $7000 from Interactive Offers for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between September 29, 2025 and October 3, 2025. Other than the compensation received for this advertisement sent to subscribers, Daily Options Signals and its principals are not affiliated with either NanoViricides, Inc (NYSE: NNVC) or Interactive Offers. Daily Options Signals and StockEarnings its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither Daily Options Signals and StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Daily Options Signals and StockEarnings to buy or sell any security. Daily Options Signals and StockEarnings has not evaluated the accuracy of any claims made in this advertisement. Daily Options Signals and StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc (NYSE: NNVC) on Smallcaps Daily website for additional information about the relationship between Interactive Offers and NanoViricides, Inc (NYSE: NNVC). Your privacy is very important to us. If you no longer wish to receive email from DailyOptionsSignals.com, please click Unsubscribe. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com